Introduction
It is estimated that over 300,000 women in the United States have a diagnosis of cervical intraepithelial neoplasia (CIN) II-III, the precursor to cervical cancer. 1 The annual incidence of CIN II-III is estimated at 1.5 per 1000 women annually. [2] [3] Overall, the risk of progression of CIN II lesions to cancer is around 5% and the risk of progression to CIN III is 20%. 4 A diagnosis of CIN III however, carries a 12% risk of progression to cancer. Another factor to consider is the cost of treatment. In one study, the costs per episode of care were higher for CIN II-III than CIN I ($1,634 vs $1,084) with an estimated annual burden per 1,000 US women of $1,803 for CIN II-III. 2 Patients with CIN II-III lesions are often referred to tertiary/academic care centers for treatment. A survey of 126 hospitals found 50% required internal review of outside slide material before surgical intervention, while 75% of academic institutions required in-house review of outside pathology. 5 The goal of this secondary review was reduction in error by redundancy. A 21 month review at The Johns Hopkins Hospital found the rate of major diagnostic disagreement ranged from 1 to 3% across all organ sites. 6 Reviews of gynecologic oncology patients have found 4.7 to 6.8% of cases resulted in a change in diagnosis that had major prognostic implications. [7] [8] Regarding CIN II-III specifically, most of the variability in diagnosis seems to stem from the diagnosis of CIN II. This is due to the heterogeneity of CIN II lesions and discrepancies between different pathologists. 9 This is clinically important because the threshold for treatment is CIN II, with exceptions for management in younger women. [10] [11] The largest study to identify variability in pathology between clinical pathologists and academic pathologists was a multicenter randomized control trial, the ASCUS-LSIL Triage Study (ALTS). 12 They found that interpretation of CIN I by the clinical center was corroborated by the quality control group in only 42.6% biopsies. 12 Alternatively, an equal proportion of originally diagnosed CIN I biopsies (41.0%) were interpreted as negative by the pathology quality control group. Indeed, interpathologist variability regarding the diagnosis of CIN has been identified in multiple studies. 13 The purpose of this study was to determine if review of outside pathology at an academic medical center resulted in a difference in the diagnosis and subsequent treatment plan for women referred with CIN, and explore the cost associated with the secondary pathology review. Fifty-two percent denied tobacco use. The most commonly reported form of birth control was oral contraceptives (38%) followed by medroxyprogesterone injection (22%). (Table 1) The internal pathology review resulted in a change of diagnosis for 11 of the 54 cases (20%). Of which 5 of 11 (45%) were upgraded from CIN II to CIN III and 6 of 11 (55%) were downgraded from CIN III to CIN II. None of the pathology reviews resulted in a change in treatment plan. -the recommendation for treatment was based on treatment of high grade lesions (encompassing CIN II/III) and the pathology reviews did not change from high grade to low grade or vice-versa.
Materials and Methods

Participants
The total amount charged for the internal pathology review was $14,679 with the average charge per patient $272 ($228-470) . Nine patients were charged between $456-470 because two separate pathologists reviewed the outside slides (review with internal consultation). The insurance payers were evenly dispersed between Iowa Care (state form of Medicaid) and private insurance (43% vs 44%) with an average cost of $6500 billed for the entire visit including pathology review, colposcopy, and treatment if it was performed.
Regarding the pathology review charge, the total amount captured by insurance was $1,709 which left the remaining amount of $12,969 (88%) uncovered, with the hospital absorbing the cost. Furthermore, among the uncovered charges, six patients did not present for evaluation and treatment despite referral and pathology review, comprising $1722 of the uncovered charges.
Discussion
The introduction of cervical screening with cytology has significantly reduced morbidity and mortality related to cervical cancer in developed nations. 15 This is due to the detection of both preinvasive changes as well as invasive cancer at earlier stages which allows for earlier treatment. 15 When abnormal cytology and histology is identified, patients may be referred to another facility for further evaluation and management. There is limited data to support or refute whether review of outside pathology for diagnostic confirmation is necessary or cost effective especially for CIN. One could argue that review of outside pathology prior to treatment would potentially guard against needless treatment of CIN. This is especially important in younger populations that desire fertility. In a study published in the Journal of the American Medical Society, treatment for CIN was not associated with increased risk of total preterm delivery or spontaneous preterm delivery but did reveal an increased risk of preterm premature rupture of membranes. 16 As noted previously, this is clinically relevant as CIN II is often the threshold for treatment and may present as a transient process especially in younger women. [11] [12] [13] While our study demonstrated that up to 20% of cytology and pathology diagnoses were changed on review, none of the changes resulted in a modification of the treatment plan. 14 Cytological specimens accounted for no major discrepancies. 14 Our results did reveal significant cost added to each review with up to 88% of the charges unpaid. This adds to the enormous cost of human papillomavirus (HPV) related disease including CIN. In 2010, the overall direct cost burden of diagnosis and management of HPVassociated disease was estimated to be 8.0 billion dollars. 17 Approximately $6.6 billion (82.3%) was for screening and associated follow-up. 17 Our study is limited by the time period data were collected from. Given newer screening guidelines published in 2012, this same study conducted more recently might yield different results. Our study is subject to limitations in methodology including single institution retrospective cohort study with a small sample size. An attempt was made to extract data effectively from electronic medical records. To limit selection bias, all patients with outside specimens were included. The small sample size is a limitation in that major discrepancies affecting management may have been identified if all patients referred for treatment had specimens available for review (54 of 78 had pathology material available for review). Further studies are needed to validate the results and to determine if there is a cost reduction achieved by avoiding a secondary pathology review for CIN. Additionally, given recent implementation of molecular pathology techniques to aid in the diagnosis of CIN II, it would be interesting to see if new techniques improve diagnostic accuracy and consistency among pathologists.
Based on the findings of this study, mandatory review of outside pathology prior to treatment of cervical intraepithelial neoplasia at a referral center may not necessarily be of value and should possibly be left to the clinical judgment of the treating physician.
